Systemic cancer therapy: achievements and challenges that lie ahead

Michael O Palumbo, Petr Kavan, Wilson H Miller Jr, Lawrence Panasci, Sarit Assouline, Nathalie Johnson, Victor Cohen, Francois Patenaude, Michael Pollak, R Thomas Jagoe, Gerald Batist, Michael O Palumbo, Petr Kavan, Wilson H Miller Jr, Lawrence Panasci, Sarit Assouline, Nathalie Johnson, Victor Cohen, Francois Patenaude, Michael Pollak, R Thomas Jagoe, Gerald Batist

Abstract

In the last half of the century, advances in the systemic therapy of cancer, including chemotherapy, hormonal therapy, targeted therapy, and immunotherapy have been responsible for improvements in cancer related mortality in developed countries even as the population continues to age. Although such advancements have yet to benefit all cancer types, systemic therapies have led to an improvement in overall survival in both the adjuvant and metastatic setting for many cancers. With the pressure to make therapies available as soon as possible, the side-effects of systemic therapies, in particular long-term side-effects are not very well characterized and understood. Increasingly, a number of cancer types are requiring long-term and even lifelong systemic therapy. This is true for both younger and older patients with cancer and has important implications for each subset. Younger patients have an overall greater expected life-span, and as a result may suffer a greater variety of treatment related complications in the long-term, whereas older patients may develop earlier side-effects as a result of their frailty. Because the incidence of cancer in the world will increase over the next several decades and there will be more people living with cancer, it is important to have an understanding of the potential side-effects of new systemic therapies. As an introductory article, in this review series, we begin by describing some of the major advances made in systemic cancer therapy along with some of their known side-effects and we also make an attempt to describe the future of systemic cancer therapy.

Keywords: chemotherapy; hormonal therapy; immunotherapy; systemic therapy; targeted therapy; toxicity.

References

    1. Adam R., Wicherts D. A., de Haas R. J., Ciacio O., Lévi F., Paule B., et al. (2009). Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J. Clin. Oncol. 27 1829–1835
    1. Aisenberg A. C., Finkelstein D. M., Doppke K. P., Koerner F. C., Boivin J.-F., Willett C. G. (1997). High risk of breast carcinoma after irradiation of young women with Hodgkin’s disease. Cancer 79 1203–1210
    1. Aleman B. M., van den Belt-Dusebout A. W., Klokman W. J., Van’t Veer M. B., Bartelink H., van Leeuwen F. E., et al. (2003). Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J. Clin. Oncol. 21 3431–3439
    1. Amir E., Seruga B., Niraula S., Carlsson L, Ocaña A. (2011). Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J. Natl. Cancer Inst. 103 1299–1309
    1. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350 2343–2351
    1. Andre T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., et al. (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27 3109–3116
    1. Anninga J. K., Gelderblom H., Fiocco M., Kroep J. R., Taminiau A. H., Hogendoorn P. C., et al. (2011). Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur. J. Cancer 47 2431–2445
    1. Bacci G., Briccoli A., Picci P., Ferrari S. (1995). Metachronous pulmonary metastases resection in patients with Ewing’s sarcoma initially treated with adjuvant or neoadjuvant chemotherapy. Eur. J. Cancer 31A 999–1001
    1. Bacci G., Rocca M., Salone M., Balladelli A., Ferrari S., Palmerini E., et al. (2008). High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J. Surg. Oncol. 98 415–420
    1. Beadle G. P., Baade P., Fritschi L. (2009). Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers. Ann. Oncol. 20 103–109
    1. Berry D. A., Cirrincione C., Henderson I. C., Citron M. L., Budman D. R., Goldstein L. J., et al. (2006). Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295 1658–1667
    1. Blanke C. D., Demetri G. D., von Mehren M., Heinrich M. C., Eisenberg B., Fletcher J. A., et al. (2008). Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26 620–625
    1. Bokemeyer C., Berger C. C., Hartmann J. T., Kollmannsberger C., Schmoll H. J., Kuczyk M. A., et al. (1998). Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Cancer 77 1355–1362
    1. Bowers D. C., Liu Y., Leisenring W., McNeil E., Stovall M., Gurney J. G., et al. (2006). Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J. Clin. Oncol. 24 5277–5282
    1. Bowles E. J., Wellman R., Feigelson H. S., Onitilo A. A., Freedman A. N., Delate T., et al. (2012). Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J. Natl. Cancer Inst. 104 1293–1305
    1. Brydoy M., Oldenburg J., Klepp O., Bremnes R. M., Wist E. A., Wentzel-Larsen T., et al. (2009). Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J. Natl. Cancer Inst. 101 1682–1695
    1. Castellino S. M., Geiger A. M., Mertens A. C., Leisenring W. M., Tooze J. A., Goodman P., et al. (2011). Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 117 1806–1816
    1. Chabner B. A., Roberts T. G. , Jr (2005). Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 5 65–72
    1. Chapman P. B., Hauschild A., Robert C., Haanen J. B., Ascierto P., Larkin J., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364 2507–2516
    1. Chia S. K., Speers C. H., D’Yachkova Y., Kang A., Malfair-Taylor S., Barnett J., et al. (2007). The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110 973–979
    1. Choueiri T. K., Schutz F. A., Je Y., Rosenberg J. E, Bell- munt J. (2010). Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J. Clin. Oncol. 28 2280–2285
    1. Chow E. J., Friedman D. L., Yasui Y., Whitton J. A., Stovall M., Robison L. L., et al. (2007). Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J. Pediatr. 150, 370.e1–375.e1
    1. Cuppone F., Bria E., Verma S., Pritchard K. I., Gandhi S., Carlini P., et al. (2008). Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 112 260–267
    1. Deininger M., O’Brien S. G., Guilhot F., Goldman J. M., Hochhaus A., Hughes T. P., et al. (2009). International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated withiImatinib (abstract 1126). Blood 114 126
    1. Devarahally S. R., Severson R. K., Chuba P., Thomas R., Bhambhani K., Hamre M. R. (2003). Second malignant neoplasms after primary central nervous system malignancies of childhood and adolescence. Pediatr. Hematol. Oncol. 20 617–625
    1. Dores G. M., Metayer C., Curtis R. E., Lynch C. F., Clarke E. A., Glimelius B., et al. (2002). Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J. Clin. Oncol. 20 3484–3494
    1. Dowsett M., Cuzick J., Ingle J., Coates A., Forbes J., Bliss J., et al. (2010). Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 28 509–518
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C., Godwin J., Gray R., Clarke M., Cutter D., et al. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378 771–784
    1. Efficace F., Baccarani M., Breccia M., Alimena G., Rosti G., Cottone F., et al. (2011). Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118 4554–4560
    1. Escudier B., Eisen T., Stadler W. M., Szczylik C., Oudard S., Staehler M., et al. (2009). Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27 3312–3318
    1. Fossa S. D., Aass N., Winderen M., Börmer O. P., Olsen D. R. (2002). Long-term renal function after treatment for malignant germ-cell tumours. Ann. Oncol. 13 222–228
    1. Fouladi M., Chintagumpala M., Ashley D., Kellie S., Gururangan S., Hassall T., et al. (2008). Amifostine protects aga- inst cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J. Clin. Oncol. 26 3749–3755
    1. Fouladi M., Gilger E., Kocak M., Wallace D., Buchanan G., Reeves C., et al. (2005). Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J. Clin. Oncol. 23 7152–7160
    1. Fukuoka M., Wu Y. L., Thongprasert S., Sunpaweravong P., Leong S. S., Sriuranpong V., et al. (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29 2866–2874
    1. Gambacorti-Passerini C., Antolini L., Mahon F. X., Guilhot F., Deininger M., Fava C., et al. (2011). Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J. Natl. Cancer Inst. 103 553–561
    1. Gatta G., Capocaccia R., Stiller C., Kaatsch P., Berrino F., Terenziani M., et al. (2005). Childhood cancer survival trends in Europe: a EUROCARE Working Group Study. J. Clin. Oncol. 23 3742–3751
    1. Gennari A., Conte P., Rosso R., Orlandini C., Bruzzi P. (2005). Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104 1742–1750
    1. Gilman A., Philips F. S. (1946). The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science 103 409–436
    1. Ginsberg J. P., Goodman P., Leisenring W., Ness K. K., Meyers P. A., Wolden S. L., et al. (2010). Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J. Natl. Cancer Inst. 102 1272–1283
    1. Hodgson D. C., Gilbert E. S., Dores G. M., Schonfeld S. J., Lynch C. F., Storm H., et al. (2007). Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J. Clin. oncol. 25 1489–1497
    1. Hodi F. S., O’Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 711–723
    1. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356 2271–2281
    1. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 2335–2342
    1. Hussain M., Tangen C. M., Higano C. S., Crawford E. D., Liu G., Wilding G., et al. (2012). Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial (abstract #4). J. Clin. Oncol.
    1. Iacovelli R., Palazzo A., Mezi S., Morano F., Naso G., Cortesi E. (2012). Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol. 51 873–879
    1. Ise T., Kishi K., Imashuku S., Tsukada M., Tsukimoto I., Tsujino G., et al. (1986). Testicular histology and function following long-term chemotherapy of acute leukemia in children and outcome of the patients who received testicular biopsy. Am. J. Pediatr. Hematol. Oncol. 8 288–293
    1. Joensuu H., Eriksson M., Sundby Hall K., Hartmann J. T., Pink D., Schütte J., et al. (2012). One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307 1265–1272
    1. Karapetis C. S., Khambata-Ford S., Jonker D. J., O’Callaghan C. J., Tu D., Tebbutt N. C., et al. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359 1757–1765
    1. Kozloff M., Yood M. U., Berlin J., Flynn P. J., Kabbinavar F. F., Purdie D. M., et al. (2009). Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14 862–870
    1. Kwak E. L., Bang Y. J., Camidge D. R., Shaw A. T., Solomon B., Maki R. G., et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363 1693–1703
    1. Lacouture M. E., Reilly L. M., Gerami P., Guitart J. (2008). Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann. Oncol. 19 1955–1961
    1. Laughton S. J., Merchant T. E., Sklar C. A., Kun L. E., Fouladi M., Broniscer A., et al. (2008). Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J. Clin. Oncol. 26 1112–1118
    1. Liu W., Makrauer F. L., Qamar A. A., Jänne P. A., Odze R. D. (2007). Fulminant hepatic failure secondary to erlotinib. Clin. Gastroenterol. Hepatol. 5 917–920
    1. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23 4265–4274
    1. Masi G., Loupakis F., Pollina L., Vasile E., Cupini S., Ricci S., et al. (2009). Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann. Surg. 249 420–425
    1. Mincey B. A., Duh M. S., Thomas S. K., Moyneur E., Marynchencko M., Boyce S. P., et al. (2006). Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin. Breast Cancer 7 127–132
    1. Mok T. S., Wu Y. L., Thongprasert S., Yang C. H., Chu D. T., Saijo N., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 947–957
    1. Motzer R. J., Escudier B., Oudard S., Hutson T. E., Porta C., Bracarda S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 449–456
    1. Motzer R. J., Escudier B., Oudard S., Hutson T. E., Porta C., Bracarda S., et al. (2010). Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116 4256–4265
    1. Motzer R. J., Hutson T. E., Tomczak P., Michaelson M. D., Bukowski R. M., Oudard S., et al. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27 3584–3590
    1. Motzer R. J., Hutson T. E., Tomczak P., Michaelson M. D., Bukowski R. M., Rixe O., et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356 115–124
    1. Neglia J. P., Meadows A. T., Robison L. L., Kim T. H., Newton W. A., Ruymann F. B., et al. (1991). Second neoplasms after acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 325 1330–1336
    1. Nesbit M. E., Jr., Gehan E. A., Burgert E. O., Jr., Vietti T. J., Cangir A., Tefft M., et al. (1990). Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J. Clin. Oncol. 8 1664–1674
    1. Ng A. K., Bernardo M. P., Weller E., Backstrand K. H., Silver B., Marcus K. C., et al. (2002). Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J. Clin. Oncol. 20 2101–2108
    1. Nguyen P. L., Je Y., Schutz F. A., Hoffman K. E., Hu J. C., Parekh A., et al. (2011). Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306 2359–2366
    1. O’Sullivan J. M., Huddart R. A., Norman A. R., Nicholls J., Dearnaley D. P., Horwich A. (2003). Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncol. 14 91–96
    1. Ou S. H., Azada M., Dy J., Stiber J. A. (2011). Asymptomatic profound sinus bradycardia (heart rate </ = 45) in non-small cell lung cancer patients treated with crizotinib. J. Thorac. Oncol. 6 2135–2137
    1. Packer R. J., Gajjar A., Vezina G., Rorke-Adams L., Burger P. C., Robertson P. L., et al. (2006). Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 24 4202–4208
    1. Partridge A. H., Ruddy K. J. (2007). Fertility and adjuvant treatment in young women with breast cancer. Breast 16(Suppl. 2) S175–S181
    1. Pellegrinotti M., Fimognari F. L., Franco A., Repetto L., Pastorelli R. (2009). Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. Ann. Pharmacother. 43 542–545
    1. Perez E. A., Suman V. J., Davidson N. E., Sledge G. W., Kaufman P. A., Hudis C. A., et al. (2008). Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J. Clin. Oncol. 26 1231–1238
    1. Postma T. J., Vermorken J. B., Liefting A. J., Pinedo H. M., Heimans J. J. (1995). Paclitaxel-induced neuropathy. Ann. Oncol. 6 489–494
    1. Pui C. H., Behm F. G., Raimondi S. C., Dodge R. K., George S. L., Rivera G. K., et al. (1989). Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N. Engl. J. Med. 321 136–142
    1. Pui C. H., Sandlund J. T., Pei D., Campana D., Rivera G. K., Ribeiro R. C., et al. (2004). Improved outcome for children with acute lymphoblastic leukemia: results of total therapy study XIIIB at St Jude Children’s Research Hospital. Blood 104 2690–2696
    1. Relling M. V., Rubnitz J. E., Rivera G. K., Boyett J. M., Hancock M. L., Felix C. A., et al. (1999). High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354 34–39
    1. Rini B. I., Escudier B., Tomczak P., Kaprin A., Szczylik C., Hutson T. E., et al. (2011). Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378 1931–1939
    1. Rini B. I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L., et al. (2007). Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 99 81–83
    1. Robert C., Thomas L., Bondarenko I., O’Day S., Weber J., Garbe C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364 2517–2526
    1. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 239–246
    1. Rutkowski S., Bode U., Deinlein F., Ottensmeier H., Warmuth-Metz M., Soerensen N., et al. (2005). Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med. 352 978–986
    1. Sankila R., Garwicz S., Olsen J. H., Döllner H., Hertz H., Kreuger A., et al. (1996). Risk of subsequent malignant neoplasms among 1,641 Hodgkin’s disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J. Clin. Oncol. 14 1442–1446
    1. Schaapveld M., Visser O., Louwman M. J., de Vries E. G., Willemse P. H., Otter R., et al. (2008). Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J. Clin. Oncol. 26 1239–1246
    1. Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A. M., Haenel M., et al. (2002). Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359 2065–2071
    1. Shahinian V. B., Kuo Y. F., Freeman J. L., Goodwin J. S. (2005). Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352 154–164
    1. Siegel R., Ward E., Brawley O., Jemal A. (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61 212–236
    1. Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 783–792
    1. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365 1273–1283
    1. Smith M. R., Saad F., Egerdie B., Sieber P. R., Tammela T. L., Ke C., et al. (2012). Sarcopenia during androgen-deprivation therapy for prostate cancer. J. Clin. Oncol. 30 3271–3276
    1. Sternberg C. N., Davis I. D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28 1061–1068
    1. Swerdlow A. J., Barber J. A., Hudson G. V., Cunningham D., Gupta R. K., Hancock B. W., et al. (2000). Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J. Clin. Oncol. 18 498–509
    1. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., et al. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25 1658–1664
    1. Van Cutsem E., Siena S., Humblet Y., Canon J. L., Maurel J., Bajetta E., et al. (2008). An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann. Oncol. 19 92–98
    1. van der Pal H. J., van Dalen E. C., van Delden E., van Dijk I. W., Kok W. E., Geskus R. B., et al. (2012). High risk of symptomatic cardiac events in childhood cancer survivors. J. Clin. Oncol. 30 1429–1437
    1. van Leeuwen F. E., Klokman W. J., Stovall M., Dahler E. C., van’t Veer M. B., Noordijk E. M., et al. (2003). Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J. Natl. Cancer Inst. 95 971–980
    1. van Leeuwen F. E., Klokman W. J., Stovall M., Hagenbeek A., van den Belt-Dusebout A. W., Noyon R., et al. (1995). Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J. Natl. Cancer Inst. 87 1530–1537
    1. Verma D., Kantarjian H., Strom S. S., Rios M. B., Jabbour E., Quintas-Cardama A., et al. (2011). Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118 4353–4358
    1. Viviani S., Zinzani P. L., Rambaldi A., Brusamolino E., Levis A., Bonfante V., et al. (2011). ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N. Engl. J. Med. 365 203–212
    1. von der Weid N., Swiss Pediatric Oncology Group (2001). Late effects in long-term survivors of ALL in childhood: experiences from the SPOG late effects study. Swiss Med. Wkly 131 180–187
    1. Weickhardt A. J., Rothman M. S., Salian-Mehta S., Kiseljak-Vassiliades K., Oton A. B., Doebele R. C., et al. (2012). Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 118 5302–5309
    1. Wilke D. R., Parker C., Andonowski A., Tsuji D., Catton C., Gospodarowicz M., et al. (2006). Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. BJU Int. 97 963–968
    1. Zhou C., Wu Y. L., Chen G., Feng J., Liu X. Q., Wang C., et al. (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12 735–742
    1. Zhu X., Stergiopoulos K., Wu S. (2009). Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 48 9–17

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit